Molecular Devices’ ScreenWorks Peak Pro Analysis Module for the FLIPR Tetra System analyzes multi-peak calcium oscillation responses of cells and beating cardiomyocytes, to characterize cardiotoxic and cardioactive compounds during a high throughput screen.
Researchers can better understand in vitro cardiomyocyte function and the impact of toxic compounds that induce cardiac abnormalities through the system, which performs cardiotoxicity safety testing early in the drug discovery pipeline, allowing researchers to fail toxic compounds sooner, and prioritize the most promising leads to take forward.
The system allows users to estimate efficacy and dosing of a drug candidate prior to progression into clinical studies. Both the specific absorption rate (SAR) and medicinal chemistry studies can be directed on a larger scale, when compared to more labor intensive traditional assay methods. The software enables increased throughput and cuts time to results by delivering data analysis for multiple parameters in less than five minutes.
The module, when used with the FLIPR Tetra System and the FLIPR Calcium 5 Assay Kit, provides a high throughput screening method for changes in intracellular calcium associated with cardiomyocyte contractions. Integrated fluidics enables simultaneous evaluation of up to 1536 wells in less than two minutes, and gives users the ability to determine the immediate impact of compounds on cells. The method may be used with primary and stem-cell derived, human, and mouse cardiomyocytes.
